2005
Increased salivary cortisol after waking in depression
Bhagwagar Z, Hafizi S, Cowen P. Increased salivary cortisol after waking in depression. Psychopharmacology 2005, 182: 54-57. PMID: 15991000, DOI: 10.1007/s00213-005-0062-z.Peer-Reviewed Original ResearchConceptsSalivary cortisolMedication-free subjectsMorning cortisol secretionCommunity-based sampleExaggerated releaseCortisol secretionAcute depressionHealthy controlsMajor depressionCortisol levelsDepressed subjectsCortisolMore cortisolDepressionPatientsRecent studiesSubjectsHypersecretionPathophysiologyObjectiveToMinMethodsWeResultsInControlSecretion
2003
Increase in Concentration of Waking Salivary Cortisol in Recovered Patients With Depression
Bhagwagar Z, Hafizi S, Cowen P. Increase in Concentration of Waking Salivary Cortisol in Recovered Patients With Depression. American Journal Of Psychiatry 2003, 160: 1890-1891. PMID: 14514508, DOI: 10.1176/appi.ajp.160.10.1890.Peer-Reviewed Original ResearchConceptsSalivary cortisol levelsCortisol levelsDepressed patientsAcute major depressionComorbid medical conditionsHPA axis abnormalitiesWithdrawal of medicationCoronary heart diseaseElevated plasma cortisol levelsHPA axis activityHealthy comparison subjectsPlasma cortisol levelsHealthy comparison groupClinical recoveryAxis abnormalitiesRecovered patientsAdrenal axisFurther episodesAxis activityHeart diseaseMajor depressionMedical conditionsComparison subjectsPatientsDepressed subjectsContrasting effects of citalopram and reboxetine on waking salivary cortisol
Harmer C, Bhagwagar Z, Shelley N, Cowen P. Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology 2003, 167: 112-114. PMID: 12605289, DOI: 10.1007/s00213-003-1417-y.Peer-Reviewed Original ResearchConceptsHPA axis activitySalivary cortisolAxis activitySelective noradrenaline re-uptake inhibitorNoradrenaline re-uptake inhibitorSelective serotonin re-uptake inhibitor citalopramConclusionsShort-term treatmentDifferent antidepressant medicationsHPA axis functionEffect of citalopramRe-uptake inhibitorsDouble-blind designShort-term treatmentBasal salivary cortisol levelsDiurnal salivary cortisolSalivary free cortisolSalivary cortisol levelsAntidepressant administrationRationaleAcute administrationReboxetine treatmentAntidepressant medicationAntidepressant treatmentAxis functionHPA axisAdrenal axisRisperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Sharpley A, Bhagwagar Z, Hafizi S, Whale W, Gijsman H, Cowen P. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. The Journal Of Clinical Psychiatry 2003, 64: 192-6. PMID: 12633128, DOI: 10.4088/jcp.v64n0212.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAntidepressive AgentsAntipsychotic AgentsCross-Over StudiesDepressive DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPersonality InventoryPlacebosPolysomnographyPsychiatric Status Rating ScalesRisperidoneSleep, REMTreatment OutcomeWakefulnessConceptsRapid eye movement (REM) sleepEye movement sleepDepressed patientsHealthy volunteersRisperidone treatmentMovement sleepREM sleepMedication-resistant depressed patientsTreatment-resistant depressed patientsConventional antidepressant medicationAntidepressant-like effectsAntipsychotic agent risperidoneDepression Rating ScaleMajor depressive disorderDSM-IV criteriaPatients meritRisperidone additionRisperidone augmentationAntidepressant medicationRisperidone administrationSingle doseTherapeutic dosesAugmentation agentsDepressive disorderHealthy subjects